Taylor C J, Hirsch N P, Kullmann D M, Howard Robin S
Batten/Harris Neuromedical Intensive Care Unit, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK.
J Neurol. 2017 Mar;264(3):564-569. doi: 10.1007/s00415-016-8380-0. Epub 2017 Jan 16.
We report a retrospective review of 110 patients with acute Guillain-Barré syndrome (GBS) admitted to a specialised intensive care unit (ICU) in a tertiary referral centre over a 25 year period, the start of which coincided with the widespread introduction of plasma exchange (PE) and intravenous immunoglobulin (IVIG). The results were analysed by comparing 52 patients admitted in the first decade (1991-2000; Group 1) with 58 patients admitted between 2001-2014 (Group 2). Patients in both groups were comparable with respect to age and sex, and had a similar incidence and range of ICU complications. They received a comparable range of immunomodulatory treatments including IVIG and PE. However, the delay from presentation to referral to the tertiary ICU was longer in patients in Group 2. They also required mechanical ventilation for a longer duration, and had longer ICU and hospital stays. In Group 2, there was a higher incidence of axonal neuropathy (51%, compared to 24% in Group 1). Despite the longer delay to referral, the prevalence of axonal neuropathy and the duration of ventilation, overall mortality showed a downward trend (Group 1: 13.5%; Group 2: 5.2%). There was no late mortality in either group after step-down to neuro-rehabilitation or following discharge home or to the referring hospital. The rehabilitation outcomes were similar. This data show a shift in the pattern of referral to a tertiary referral ICU between the first and second decades following the wider availability of IVIG and PE for the treatment of GBS. The possible causes and implications of these findings are discussed.
我们对一家三级转诊中心的专科重症监护病房(ICU)收治的110例急性吉兰 - 巴雷综合征(GBS)患者进行了回顾性研究,研究时间跨度为25年,开始时间恰逢血浆置换(PE)和静脉注射免疫球蛋白(IVIG)广泛应用之时。通过比较第一个十年(1991 - 2000年;第1组)收治的52例患者与2001 - 2014年收治的58例患者(第2组)来分析结果。两组患者在年龄和性别方面具有可比性,ICU并发症的发生率和范围相似。他们接受了包括IVIG和PE在内的类似范围的免疫调节治疗。然而,第2组患者从出现症状到转诊至三级ICU的延迟时间更长。他们还需要更长时间的机械通气,并且在ICU和医院的住院时间更长。在第2组中,轴索性神经病的发生率更高(51%,而第1组为24%)。尽管转诊延迟更长,但轴索性神经病的患病率和通气持续时间、总体死亡率呈下降趋势(第1组:13.5%;第2组:5.2%)。在降级至神经康复阶段后或出院回家或转至转诊医院后,两组均无晚期死亡病例。康复结果相似。这些数据显示了在IVIG和PE更广泛用于治疗GBS后的第一个和第二个十年间,转诊至三级转诊ICU的模式发生了变化。讨论了这些发现的可能原因和影响。